Shanghai Pharmaceuticals (HKG:2607, SHA:601607) completed the analysis of the results of the Phase II clinical trial of LT3001, a drug used for the treatment of acute stroke and acute ischemic stroke, according to a Shanghai Stock Exchange filing on Saturday.
The trial found that the drug was generally safe and well tolerated and it showed preliminary efficacy among subjects within 90 days of treatment.
The rights of the drug were bought from Shuntian Pharmaceutical Biotech in 2019 and it was approved for clinical trials in 2020, the Chinese pharmaceutical company said.
The company's shares fell 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments